In vivo Effect of I'm-Yunity™ on Hepatic Cytochrome P450 3A4

References

• Cui J, Chisti Y. Polysaccharopeptides of Coriolus versicolor: Physiological activity, uses, and production. Biotechnol Adv 2003; 21: 109–22
   PubMed Web of Science ®Google Scholar
• Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton J. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35: 35–98
   PubMed Web of Science ®Google Scholar
• Cummins C L, Wu C, Benet L Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474–89
   PubMed Web of Science ®Google Scholar
• Thummel K E, Wilkinson G R. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389–430
   PubMed Web of Science ®Google Scholar
• Markowitz J S, Donovan J L, De Vane C L, Taylor R M, Ruan Y, Wang J S, et al. Effect of St John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. J Amer Med Assoc 2003; 11: 1500–4
   Google Scholar
• Ng T B. A review of research on the protein-bound polysaccharide from the mushroom Coriolus versicolor. Gen Pharmac 1998; 30: 1–4
   PubMedGoogle Scholar
• , Dietary Supplement Health and Education Act of 1994 [www.fda.gov/opacom/laws/dshea.html].
   Google Scholar
• Watkins P B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171–84
   PubMedGoogle Scholar
• Rivory L P, Slaviero K A, Hoskins J M, Clarke S J. The erythromycin breath test for the prediction of drug clearance. Clin Pharmacokinet 2001; 40: 151–8
   PubMed Web of Science ®Google Scholar
• Metabolic Solutions, Inc. Erythromycin breath test (package insert). Nashua, NH 2004
   Google Scholar
• Chiou W L, Jeong H Y, Wu T C, Ma C. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin Pharmacol Ther 2001; 70: 305–10
   PubMed Web of Science ®Google Scholar
• McCune J S, Hawke R L, Le Cluyse E L, Gillenwater H H, Hamilton G, Ritchie J, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000; 68: 356–66
   PubMed Web of Science ®Google Scholar
• DeVane C L, Donovan J L, Liston H L, Markowitz J S, Cheng K T, Risch S C, et al. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharm 2004; 24: 4–10
   PubMed Web of Science ®Google Scholar
• Floyd M D, Gervasini G, Masica A L, Mayo G, George A L, Bhat K, et al. Geno-type-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13: 595–606
   PubMedGoogle Scholar
• Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 2001; 51: 591–600
   PubMed Web of Science ®Google Scholar
• Mouly S, Lown K S, Kornhauser D, Joseph J L, Fiske W D, Benedek I H, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72: 1–9
   PubMed Web of Science ®Google Scholar
• Chu K K, Ho S S, Chow A H. Coriolus versicolor: A medicinal mushroom with promising immunotherapeutic values. J Clin Pharmacol 2002; 42: 976–84
   PubMed Web of Science ®Google Scholar
• Watkins P B, Murray S A, Winkelman L G, Heuman D M, Wrighton S A, Guzellan P S. Erythromycin breath test asan assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989; 83: 688–97
   PubMed Web of Science ®Google Scholar
• Wagner D. CYP3A4 and the EBT (letter). Clin Pharmacol Ther 1998; 64: 129
   PubMed Web of Science ®Google Scholar
• Rivory L P, Watkins P B. Erythromycin breath test. Clin Pharmacol Ther 2001; 70: 395–9
   PubMed Web of Science ®Google Scholar
• Kivisto K T, Kroemer H K. Use of prove drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37: 40–8S
   PubMed Web of Science ®Google Scholar
• Watkins P B, Turgeon D K, Saenger P, Lown K S, Kolars J C, Hamilton T, et al. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52: 265–73
   PubMed Web of Science ®Google Scholar
• Paine M F, Wagner D A, Hoffmaster K A, Watkins P B. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between oral erythromycin breath test and rifampin. Clin Pharmacol Ther 2002; 72: 524–35
   PubMed Web of Science ®Google Scholar
• Gharaibeh M N, Gillen L P, Osborne B, Schwartz J I, Waldman S A. Effect of multiple doses of rifampin on the [14C-N-methyl] erythromycin breath test in healthy volunteers. J Clin Pharmacol 1998; 38: 492–5
   PubMed Web of Science ®Google Scholar
• McCrea J, Prueksaritanont T, Gertz B J, Carides A, Gillen L, Antonello S, et al. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol 1999; 39: 1212–20
   PubMed Web of Science ®Google Scholar
• Sun H, Huang Y, Frassetto L, Benet L Z. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 2004; 32: 1239–46
   PubMed Web of Science ®Google Scholar
• Marzolini C, Tirona R G, Kim R B. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 2004; 5: 273–82
   PubMed Web of Science ®Google Scholar